Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab

Background: The IFCT-1603 trial evaluated atezolizumab in small cell lung cancer (SCLC). The purpose of the present study was to determine whether circulating tumor DNA (ctDNA), prospectively collected at treatment initiation, was associated with the prognosis of SCLC, and whether it identified pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Herbreteau, Guillaume, Langlais, Alexandra, Greillier, Laurent, Audigier-Valette, Clarisse, Uwer, Lionel, Hureaux, José, Moro-Sibilot, Denis, Guisier, Florian, Carmier, Delphine, Madelaine, Jeannick, Otto, Josiane, Souquet, Pierre-Jean, Gounant, Valérie, Merle, Patrick, Molinier, Olivier, Renault, Aldo, Rabeau, Audrey, Morin, Franck, Denis, Marc G, Pujol, Jean-Louis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760916/
https://www.ncbi.nlm.nih.gov/pubmed/33261056
http://dx.doi.org/10.3390/jcm9123861

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760916/
https://www.ncbi.nlm.nih.gov/pubmed/33261056
http://dx.doi.org/10.3390/jcm9123861

Ejemplares similares